Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a ...

Strengthened cash position expected to support the Company through first substantive data readout in its Phase 2 ovarian cancer trial, with enrollment scheduled to begin H1 2025 Enrollment in new ...

EDC solutions offer many benefits for platform trials. Credit: via Shuttetstock. As clinical research continues evolving to become more innovative and efficient, adaptive trials, specifically platform ...

As of 10:33:27 AM GMT+1. Market Open.